1 - 10 of 10

Rochelle Bagatell, MD

Rochelle Bagatell

Dr. Bagatell’s research focuses on improving therapies for children with neuroblastoma. She leads clinical research studies designed to critically evaluate current therapies for children with high-risk and relapsed disease, and is committed to conducting studies of new therapies for this population. She is currently pursuing research designed to evaluate biomarkers for response to targeted therapy in children with high-risk disease.


L. Charles Bailey, MD, PhD

L. Charles Bailey

Dr. Bailey’s research centers on the development of learning health systems. This endeavor includes the creation of methods to share data across hospitals, recognize the clinical implications of information gathered from different sources, and provide support to clinicians to use this information more effectively.


Frank M. Balis, MD

Frank M. Balis

Dr. Balis's research focuses on the clinical pharmacology of anticancer drugs, new drug development, and clinical trial design and endpoints. He studies the pharmacokinetics and pharmacodynamics of anticancer drugs and has applied pharmacological principles to clinical trial design and clinical drug development. He is developing new biomarkers to serve as surrogate endpoints of drug toxicity or efficacy in clinical trials.


Lamia P. Barakat, PhD

Lamia P. Barakat

Dr. Barakat's research is focused on examining risk-and-resilience models to characterize disease management and health-related quality of life of children with chronic health conditions and their families. Another focus of investigation is translation of these models into evidence-based assessment (family psychosocial risk screening) as well as family-based, mHealth interventions to improve disease management and to support medical decision-making for youth with cancer and their families.


David M. Barrett, MD, PhD

David M. Barrett

Dr. Barret's research program focuses on immune function of children with cancer. His research involves investigating possible immune deficiencies that result in children developing cancer and developing immune-based therapies for childhood cancer.


Jean B. Belasco, MD

Jean B. Belasco

Dr. Belasco’s clinical and research work focuses on pediatric cancers, palliative care, neuro-oncology, neurofibromatosis, and lymphatic vascular malformations.


Kristopher R. Bosse, MD

Photo of Kristopher R. Bosse

The cure rate for children with neuroblastoma is unacceptable, making it imperative that new therapies are developed. Dr. Bosse's laboratory is focused on discovering and developing new neuroblastoma cell surface immunotherapeutic targets. Along with his colleagues, Dr. Bosse's aim is to capitalize on the robust differential expression of these molecules with immune-based therapies and also define their mechanisms of overexpression and roles in tumorigenesis.


Garrett M. Brodeur, MD

Garrett M. Brodeur

Dr. Broedur’s research interests focus on nanoparticle drug delivery and cancer predisposition. He is also interested in identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals with the hope of improving outcome and reducing side effects.


Nancy J. Bunin, MD

Dr. Bunin's current research focuses on the development of hematopoietic stem cell graft engineering for allogeneic transplantation to minimize graft-versus-host disease (GVHD), promote engraftment and immune reconstitution. She has also developed protocols for rapid manufacture of viral cytotoxic T lymphocytes to treat or prevent life threatening viral infections post hematopoietic stem cell transplant.